English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Hutchison Medipharm Announces Successful Results of its Phase II Study in mCRC

Sep. 2, 2015

Hutchison MediPharma has published the results of its Phase II clinical trial of fruquintinib in metastatic colorectal cancer (“mCRC”). 

The top-line results demonstrated that the trial clearly succeeded in meeting the primary efficacy endpoint of progression-free survival (“PFS”).

The assessment of secondary efficacy endpoints, including objective response rate, disease control rate, and the overall survival rate, is ongoing, with all appearing in-line with expectations at the August 2015 five-month data cut-off.  The adverse events demonstrated in this POC study are consistent with the known safety profile for fruquintinib without major unexpected safety issues.